TCT 2017 Poster Shows Impact of Strut Thickness on Thrombogenicity in BRS
ArterioSorb™ has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model.
Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of thrombus.
Shengjui, from Nicolas Foin’s group, compared thick strut BRS (157μm, Absorb BVS, Abbott Vascular) to thin strut BRS (95μm, ArterioSorb™, Arterius) and a thin strut DES (81μm, Xience, Abbott Vascular). Scaffolds were expanded in in-vitro coronary perfusion models which were perfused with porcine blood. Thrombus formation was then evaluated.
Thin strut ArterioSorb™ showed significantly smaller thrombus area compared to Absorb BVS (p<0.01).
No difference was found between thin strut ArterioSorb™ and Xience (p=0.99).
Summary: Compared to larger strut BRS, the thin strut ArterioSorb™ BRS and metallic DES show decreased acute platelet adherence and thrombus formation. The in-vitro model suggests that clot formation on scaffolds may be modulated by strut profile.
This further corroborates the previously published endothelial shear stress data showing less disruption to the arterial blood flow for ArterioSorb™ compared to Absorb BVS.
The full poster may be viewed here:TCT 2017 Strut Thickness Impact on Thrombogenicity in BRS